Mast Therapeutics has announced that its subsidiary Aires Pharmaceuticals has signed an agreement with Philips Respironics devices for the supply of I-neb AAD handheld nebulizers for delivery of the company’s AIR001 sodium nitrite solution. AIR001 is in Phase 2 development for the treatment of heart failure with preserved ejection fraction (HFpEF).
The I-neb Adaptive Aersol Delivery (AAD) system is a handheld, battery powered vibrating mesh nebulizer.
Mast CEO Brian M. Culley said, “As we announced last month, we are accelerating activities related to our AIR001 program with support for ongoing, investigator-sponsored Phase 2 clinical studies of AIR001 being conducted at three separate prestigious research institutions. As part of this commitment, we are pleased to be working with Philips, a recognized global leader in the development of aerosol delivery devices and a leading provider of innovative solutions for the global respiratory market. Our agreement has been extended to include not only two of the Phase 2 studies of AIR001 currently underway, but also future clinical studies and will remain in place until 2020 or sooner, if replaced with a commercial supply agreement.”
Read the Mast Therapeutics press release.
